Cyted Health Expands Clinical Advisory Board to Advance US Growth

Cyted Health, a leading gastrointestinal molecular diagnostics company, today announces the expansion of its advisory panel to establish a Clinical Advisory Board. The Board, comprised of leading clinicians and researchers in gastroenterology and oncology, will provide strategic guidance as Cyted builds its portfolio of diagnostics for esophageal disease and widens its footprint in the US.

The growth of the Clinical Advisory Board follows the launch of Cyted's DETECT-ME clinical validation study, which has been enrolling patients across multiple sites in the US since March 2025. This study will validate clinical performance of Cyted’s newest assays, molecular tests for the detection of Barrett’s esophagus (BE) and esophageal neoplasia, including esophageal adenocarcinoma (EAC), using Cyted's non-endoscopic, FDA 510(k)-cleared, EndoSign® cell collection device. 

Professor Rebecca Fitzgerald OBE (pictured) who is one of Cyted’s Co-founders and  currently acts as Clinical Advisor to Cyted Health, will lead the Clinical Advisory Board to support Cyted Health’s portfolio and geographic expansion. 

Fitzgerald is Professor of Cancer Prevention and Director of the Early Cancer Institute at the University of Cambridge. One of the world’s leading experts in BE and EAC, Fitzgerald has pioneered the development of minimally invasive cell sampling coupled with biomarker tests for diagnosing upper gastrointestinal conditions. 

“These clinical and academic leaders will play an instrumental role in shaping Cyted’s portfolio of advanced diagnostic tests as we expand our presence in the United States.” Marcel Gehrung, CEO and Co-founder of Cyted Health, commented. “Their combined expertise will guide our clinical strategy and ensure that our innovations effectively meet the needs of patients and healthcare providers in our shared goal to reduce mortality from esophageal adenocarcinoma.”

Cyted Health has already demonstrated significant success across the UK’s National Health Service (NHS), where it has completed over 30,000 tests, building a robust portfolio of peer-reviewed publications and real-word data. Widespread adoption of Cyted Health’s technology in the UK’s NHS has led to earlier-stage cancer detection and improved patient outcomes. 

The following distinguished clinicians will join Professor Rebecca Fitzgerald OBE on the Clinical Advisory Board:

Julian Abrams, MD, MS

Dr Julian Abrams, MD, is a Professor of Medicine and Epidemiology at Columbia University Medical Centre. He is the Director of Clinical Research for the Division of Digestive and Liver Diseases. He specialises in caring for patients with Barrett’s esophagus and early esophageal cancer. Dr Abrams research looks at disease biomarkers, promoters of neoplasia and targets for chemoprevention. 

Jacques Bergman, MD PhD

Dr. Jacques Bergman is Professor of Gastrointestinal Endoscopy at Amsterdam’s University Medical Centre. An expert in risk-stratification of Barrett esophagus, endoscopic detection and treatment of early Barrett’s neoplasia, he has authored and co-authored over 450 peer reviewed publications.

Neena Mohan MD, FACP

Dr. Neena Mohan is a gastroenterologist and Assistant Professor at the Lewis Katz School of Medicine at Temple University in Philadelphia. Dr. Mohan specializes in the diagnosis and endoscopic management of Barrett’s Esophagus and esophageal cancer. Her research and published papers explore evaluation of Barrett's Esophagus risk factors, diagnostic approaches, surveillance techniques and endoscopic treatments. Dr. Mohan has worked extensively in educational leadership roles and advocacy in medicine. She has also served on several national committees with the ACG and ASGE and is a reviewer for multiple journals. 

Nicholas J. Shaheen, MD, MPH
Dr Shaheen is the Senior Associate Dean for Clinical Research at the University of North Carolina and Co-Director of the North Carolina Translational and Clinical Research Centre. His work on Barrett’s Esophagus, GERD and eosinophilic esophagitis is highly respected, and he is the author of over 400 publications. 

Sachin Wani, MD, FASGE, AGAF
Dr Wani is a Professor of Medicine in the Division of Gastroenterology at the University of Colorado Anschutz Medical Campus and serves as the Executive Director of the Katy O and Paul M Rady Esophageal and Gastric Center of Excellence. Dr Wani has overseen clinical trials of non-endoscopic testing for Barrett’s Esophagus and is highly committed to driving forward innovation in the sector.